Barton, J., Hariri, L. P., Tumlinson, A. R., Besselsen, D. G., Utzinger, U., Gerner, E. W., & Barton, J. K. (2006). Endoscopic optical coherence tomography and laser-induced fluorescence spectroscopy in a murine colon cancer model. Lasers in surgery and medicine, 38(4).
The diagnostic feasibility of optical coherence tomography (OCT) and laser-induced fluorescence (LIF) have been evaluated for human colorectal cancer. This study applies these technologies to a murine model of colorectal adenoma.
Yang, M., Katz, J., Barton, J. K., Lai, W., & Jean, J. (2015). Using optical coherence tomography to examine additives in Chinese Song Jun glaze. Archaeometry, 57(5), 837-855.
Barton, J. K., Tang, S., Lim, R., & Tromberg, B. J. (2007). Simultaneous optical coherence and multiphoton microscopy of skin-equivalent tissue models - art. no. 66270X. OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE TECHNIQUES III, 6627, X6270-X6270.
Bonnema, G. T., Cardinal, K. O., Williams, S. K., & Barton, J. K. (2007). Imaging stented blood vessel mimics with optical coherence tomography. LASERS IN SURGERY AND MEDICINE, 46-46.
Chandra, S., Nymeyer, A. C., Rice, P. F., Gerner, E. W., & Barton, J. K. (2017). Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model. Cancer prevention research (Philadelphia, Pa.), 10(8), 459-466.
Sulindac is an NSAID that can provide effective chemoprevention for colorectal cancer. In this study, alternative dosing regimens of sulindac were evaluated for their chemoprevention effectiveness in the azoxymethane-treated A/J mouse model of colorectal cancer. High-resolution endoscopic optical coherence tomography was utilized to time-serially measure tumor number and tumor burden in the distal colon as the biological endpoints. Four treatment groups were studied: (i) daily for 20 weeks (sulindac-daily); (ii) for 2 weeks, then no sulindac for 2 weeks, cycle repeated 5 times (sulindac-2); (iii) for 10 weeks ("on"), then no sulindac for 10 weeks ("off"; sulindac-10); and (iv) no sulindac (sulindac-none). Sulindac-2 and sulindac-daily had statistically significantly lower final tumor counts and slopes (change in number of tumors per week) when compared with sulindac-none (P 0.0001). All of the treatment groups had statistically significantly lower final tumor burdens and slopes when compared with sulindac-none (P 0.001). There was a prolonged latency period in the sulindac-10 group, with no significant difference between the "off" portion of this treatment and sulindac-none. These results suggest that, although daily doses of sulindac provide the most optimal effects, intermittent doses of sulindac in a 50% duty cycle with an overall 4-week period (sulindac-2 model) can provide highly effective chemoprevention of colorectal cancer in this model. After cessation of sulindac treatment (sulindac-10 "off"), there is no evidence of either a persistent chemopreventive effect or a rebound effect. Cancer Prev Res; 10(8); 459-66. ©2017 AACR.